Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
25021-0237-06 25021-0237 Fludarabine phosphate Fludarabine phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec. 15, 2014 June 30, 2019 In Use
25021-0239-05 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Sept. 30, 2020 No Longer Used
25021-0239-26 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Feb. 28, 2021 No Longer Used
25021-0239-52 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Aug. 31, 2020 No Longer Used
00078-1091-20 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1091-94 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-20 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-30 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-94 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
63020-0040-12 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sept. 15, 2021 In Use
63020-0040-90 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sept. 15, 2021 In Use
25021-0824-06 25021-0824 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 27, 2011 March 31, 2017 In Use
39822-2120-01 39822-2120 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous April 17, 2017 July 31, 2020 In Use
39822-2180-01 39822-2180 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous April 17, 2017 July 31, 2020 In Use
39822-2200-01 39822-2200 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous April 17, 2017 July 31, 2020 In Use
00093-7663-56 00093-7663 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 In Use
00093-7664-56 00093-7664 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 In Use
24201-0101-04 24201-0101 Valrubicin Intravesical Solution Valrubicin Intravesical Solution 40.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravesical April 23, 2019 In Use
16729-0426-05 16729-0426 GEMCITABINE GEMCITABINE 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 6, 2018 In Use
00002-5337-54 00002-5337 Abemaciclib Verzenio 150.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Oct. 6, 2017 In Use
00002-5337-63 00002-5337 Abemaciclib Verzenio 150.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 5, 2020 In Use
49315-0005-10 49315-0005 Arsenic trioxide Arsenic trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 14, 2018 In Use
50742-0438-10 50742-0438 arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 15, 2018 In Use
65162-0794-03 65162-0794 Imatinib Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 In Use
65162-0794-09 65162-0794 Imatinib Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 In Use
65162-0795-03 65162-0795 Imatinib Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 In Use
65162-0795-09 65162-0795 Imatinib Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 In Use
67877-0633-90 67877-0633 imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2019 In Use
67877-0634-30 67877-0634 imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2019 In Use
72485-0202-90 72485-0202 imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 15, 2019 In Use
72485-0203-30 72485-0203 imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 15, 2019 In Use
71288-0113-10 71288-0113 GEMCITABINE HYDROCHLORIDE GEMCITABINE 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Nov. 1, 2018 In Use
68083-0386-01 68083-0386 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov. 14, 2018 In Use
71288-0114-50 71288-0114 GEMCITABINE HYDROCHLORIDE GEMCITABINE 1.0 g/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Nov. 1, 2018 In Use
63539-0295-30 63539-0295 talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 10, 2018 In Use
68382-0997-10 68382-0997 Arsenic trioxide Arsenic trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 14, 2018 In Use
67457-0316-25 67457-0316 decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 10, 2018 In Use
00069-9144-11 00069-9144 Docetaxel Docetaxel 200.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous June 23, 2014 April 30, 2017 No Longer Used
00069-9144-22 00069-9144 Docetaxel Docetaxel 200.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous June 23, 2014 Feb. 20, 2015 No Longer Used
00409-0369-01 00409-0369 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 28, 2017 March 28, 2017 No Longer Used
67457-0531-02 67457-0531 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 28, 2018 In Use
67457-0532-08 67457-0532 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 28, 2018 In Use
69097-0516-07 69097-0516 Cyclophosphamide Cyclophosphamide 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Jan. 18, 2019 In Use
69097-0517-07 69097-0517 Cyclophosphamide Cyclophosphamide 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Jan. 18, 2019 In Use
72485-0201-01 72485-0201 azacitidine AZACITIDINE 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 10, 2018 In Use
69097-0364-36 69097-0364 Bleomycin Bleomycin 15.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous March 11, 2019 In Use
71288-0106-10 71288-0106 Bleomycin Sulfate Bleomycin 15.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous Aug. 31, 2018 In Use
71288-0107-20 71288-0107 Bleomycin Sulfate Bleomycin 30.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous Aug. 31, 2018 In Use
69539-0019-60 69539-0019 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral July 2, 2018 In Use
69539-0019-99 69539-0019 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral July 2, 2018 In Use

Found 10,000 results in 5 milliseconds — Export these results